LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Начало・Списък с акции・Krystal Biotech Inc

Krystal Biotech Inc

Затворен

СекторЗдравеопазване

275.14 1.85

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

273.25

Максимум

277

Ключови измерители
By Trading Economics
Приходи	41M 79M
Продажби	1.8M 98M
P/E Средно за сектора	40.81 121.746
Марж на печалбата	81.15
Служители	275
EBITDA	10M 50M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+17.03% upside

Дивиденти
By Dow Jones
Следващи печалби	17.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.4B 7.9B
Предишно отваряне	273.29
Предишно затваряне	275.14

Настроения в новините

By Acuity

50%

155 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

133.221 / 169.73 Подкрепа & съпротива

Krystal Biotech Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.02.2026 г., 16:32 ч. UTC

Печалби

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13.02.2026 г., 21:57 ч. UTC

Печалби

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

13.02.2026 г., 21:20 ч. UTC

Печалби

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13.02.2026 г., 21:05 ч. UTC

Придобивния, сливания и поглъщания

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13.02.2026 г., 20:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.02.2026 г., 20:45 ч. UTC

Пазарно говорене

Dollar Pares Down Early Losses -- Market Talk

13.02.2026 г., 20:39 ч. UTC

Пазарно говорене

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13.02.2026 г., 20:28 ч. UTC

Пазарно говорене

Oil Settles Week Lower -- Market Talk

13.02.2026 г., 19:51 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13.02.2026 г., 19:32 ч. UTC

Пазарно говорене

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13.02.2026 г., 19:32 ч. UTC

Пазарно говорене

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13.02.2026 г., 19:29 ч. UTC

Печалби

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13.02.2026 г., 18:18 ч. UTC

Придобивния, сливания и поглъщания

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13.02.2026 г., 17:52 ч. UTC

Печалби

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13.02.2026 г., 17:16 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13.02.2026 г., 17:10 ч. UTC

Придобивния, сливания и поглъщания

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13.02.2026 г., 16:59 ч. UTC

Печалби

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13.02.2026 г., 16:39 ч. UTC

Придобивния, сливания и поглъщания

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13.02.2026 г., 16:11 ч. UTC

Печалби

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13.02.2026 г., 16:07 ч. UTC

Пазарно говорене

Hungarian Forint Could Rise Further -- Market Talk

13.02.2026 г., 15:54 ч. UTC

Печалби

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13.02.2026 г., 15:26 ч. UTC

Пазарно говорене

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13.02.2026 г., 15:01 ч. UTC

Печалби

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13.02.2026 г., 15:00 ч. UTC

Печалби

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13.02.2026 г., 14:50 ч. UTC

Пазарно говорене

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13.02.2026 г., 14:44 ч. UTC

Печалби

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13.02.2026 г., 14:22 ч. UTC

Пазарно говорене

Печалби

Global Energy Roundup: Market Talk

13.02.2026 г., 14:21 ч. UTC

Пазарно говорене

Печалби

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13.02.2026 г., 14:13 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Move Lower -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Krystal Biotech Inc Прогноза

Ценова цел

By TipRanks

17.03% нагоре

12-месечна прогноза

Среден 316.29 USD 17.03%

Висок 338 USD

Нисък 295 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Krystal Biotech Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Krystal Biotech Inc през последните 3 месеца.

Техническа оценка

By Trading Central

133.221 / 169.73Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Настроение

By Acuity

155 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.